NCT00093977已完成3 期
An Open-label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 1,100
- 主要终点
- To determine whether darbepoetin alfa manufactured by a roler bottle technology (darbepoetin alfa RB) and darbepoetin alfa manufactured by a serum free process (darbepoetin alfa SF) have a comparable safety profile
研究概览
简要总结
The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Currently diagnosed with Chronic Kidney Disease, either receiving or not receiving dialysis
- •Currently on erythropoietic therapy
- •Controlled hypertension
- •Clinically stable
排除标准
- 未提供
研究组 & 干预措施
darbepoetin alfa SF
Experimental
干预措施: darbepoetin alfa SF (Drug)
结局指标
主要结局
To determine whether darbepoetin alfa manufactured by a roler bottle technology (darbepoetin alfa RB) and darbepoetin alfa manufactured by a serum free process (darbepoetin alfa SF) have a comparable safety profile
时间窗: Entire Study
次要结局
- To characterize laboratory parameters in subjects with CKD(Entire Study)
研究者
相似试验
撤回
1 期
Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney DiseaseAnemiaChronic Kidney DiseaseNCT01428154Amgen
已完成
2 期
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle ChemotherapyNon-Myeloid MalignanciesCancerAnemiaNCT00111462Amgen
已完成
1 期
Study on the Safety of Abatacept in Relapsing PolychondritisRelapsing PolychondritisNCT01272856Benaroya Research Institute4
已完成
1 期
3BNC117-LS and 10-1074-LS in Viremic HIV-infected IndividualsHuman Immunodeficiency VirusNCT04250636Rockefeller University6
已完成
4 期
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese SubjectsCardiovascular DiseaseNCT02705807GlaxoSmithKline10
